
    
      This is an open, multi-center, randomized trial comparing the clinical outcomes of
      haploidentical HSCTs from young non-first-degree and older first-degree donors in
      hematological malignancies. This study is indicated for patients with hematological
      malignancies including ALL, AML, MDS and NHL who are eligible to haploidentical HSCTs. 2
      groups of patients will be enrolled with 80 in each group. The clinical criteria including
      survival, relapse, transplantation-related mortality will be monitored.
    
  